Conmed/$CNMD
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Conmed
Conmed Corp is a Utica, New York-based medical equipment company that focuses on sports medicine procedures and general surgeries. The Company's products are used by surgeons and other healthcare professionals in a variety of specialties including orthopedics, general surgery, gynecology, thoracic surgery and gastroenterology. Geographically operates in USA, Europe, Middle East & Africa, Asia Pacific and North America. Majority is revenue is from USA.
Ticker
$CNMD
Sector
Primary listing
NYSE
Employees
3,900
Headquarters
Website
Conmed Metrics
BasicAdvanced
$1.4B
21.44
$2.05
0.98
$0.80
1.82%
Price and volume
Market cap
$1.4B
Beta
0.98
52-week high
$74.81
52-week low
$41.62
Average daily volume
406K
Dividend rate
$0.80
Financial strength
Current ratio
2.104
Quick ratio
0.838
Long term debt to equity
84.602
Total debt to equity
87.93
Dividend payout ratio (TTM)
38.60%
Interest coverage (TTM)
4.72%
Profitability
EBITDA (TTM)
244.283
Gross margin (TTM)
56.49%
Net profit margin (TTM)
4.75%
Operating margin (TTM)
11.42%
Effective tax rate (TTM)
25.07%
Revenue per employee (TTM)
$350,000
Management effectiveness
Return on assets (TTM)
4.15%
Return on equity (TTM)
6.60%
Valuation
Price to earnings (TTM)
21.437
Price to revenue (TTM)
1.011
Price to book
1.35
Price to tangible book (TTM)
-3.35
Price to free cash flow (TTM)
9.148
Free cash flow yield (TTM)
10.93%
Free cash flow per share (TTM)
4.804
Dividend yield (TTM)
1.82%
Forward dividend yield
1.82%
Growth
Revenue change (TTM)
4.61%
Earnings per share change (TTM)
-51.43%
3-year revenue growth (CAGR)
8.04%
10-year revenue growth (CAGR)
6.42%
3-year earnings per share growth (CAGR)
-9.72%
10-year earnings per share growth (CAGR)
5.33%
What the Analysts think about Conmed
Analyst ratings (Buy, Hold, Sell) for Conmed stock.
Bulls say / Bears say
Sales increased 6.7% year over year to $337.9 million in Q3 2025, surpassing the Zacks consensus estimate by 0.4% and highlighting strong revenue momentum.
Orthopedic Surgery revenue was $138.2 million (up 5.9% year over year) and General Surgery revenue reached $199.7 million (up 7.3% year over year) in Q3 2025, showing balanced growth across main business areas.
After Q3, the Board authorized a $150 million share buyback and committed to repurchasing at least $25 million each year, signaling a strong focus on shareholder returns.
GAAP EPS fell sharply by 94.3% year over year to $0.09 in Q3 2025, down from $1.57 the previous year, mainly due to significant one-off charges for product rationalization and consulting.
Gross margin dropped by 730 basis points to 49.2% in Q3 2025, reflecting increased costs from tariffs and supply chain issues.
The company suspended its quarterly cash dividend to prioritize the expanded share buyback program, which could discourage investors seeking regular income.
Data summarised monthly by Lightyear AI. Last updated on 10 Nov 2025.
Conmed Financial Performance
Revenues and expenses
Conmed Earnings Performance
Company profitability
Conmed News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Conmed stock?
Conmed (CNMD) has a market cap of $1.4B as of November 11, 2025.
What is the P/E ratio for Conmed stock?
The price to earnings (P/E) ratio for Conmed (CNMD) stock is 21.44 as of November 11, 2025.
Does Conmed stock pay dividends?
Yes, the Conmed (CNMD) stock pays dividends to shareholders. As of November 11, 2025, the dividend rate is $0.8 and the yield is 1.82%. Conmed has a payout ratio of 38.6% on a trailing twelve-month basis.
When is the next Conmed dividend payment date?
The next Conmed (CNMD) dividend payment date is unconfirmed.
What is the beta indicator for Conmed?
Conmed (CNMD) has a beta rating of 0.98. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.